N/A N=44 Platelet-Rich Plasma (PRP) in Reconstructive Surgery on Children With Retractable Burn Sequelae on Extremities
Burns
Primary: Median Time Between Surgery Date and Start Date Compression. — 17; 19 day — p=>0.1574
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity
Dentine Hypersensitivity
Primary: Between Treatment Comparison of the Adjusted Mean Change From Baseline of Response to Evaporative (Air) Stimuli Immediately Following Treatment on Day 5 Using a Visual…
N/A N=241 Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.
Coronary Artery Disease
Primary: In-segment Percent Diameter Stenosis at 8 Months Post-procedure — 37.4 percent diameter stenosis — p=<0.001
Phase 2 N=60 Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
Age-Related Macular Degeneration
Primary: Growth of Geographic Atrophy — 0.18; 0.19 millimeters
Phase 2 N=55 Treatment of Adult Ph+ LAL With BMS-354825
Lymphoblastic Leukemia, Acute
Primary: Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start…
Phase 1 N=21 Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
Advanced Solid Tumors · Neoplasms · Carcinoma
Primary: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) — 2; 3; 1; 2 participants
Phase 3 N=438 Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 93.8; 87.1 percentage of participants — p=0.025
Phase 4 N=63 Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.
Heart Failure (HF) · Ventricular Dysfunction, Left
Primary: To Assess Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake in Heart Failure (HF) Participants on Planar Imaging at 3 Hours 50 Minutes…
N/A N=61 Outcomes in Rotator Cuff Repair Using Graft Reinforcement
Rotator Cuff Tear
Primary: American Shoulder and Elbow Score (ASES) — 48.7; 69.4; 79.9; 85.4 units on a scale
Phase 3 N=172 THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Heart Diseases · Arrhythmia · Atrial Fibrillation
Primary: The Rate of Subjects Who Were Free From Documented Symptomatic Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes Through 12-month…
Phase 2 N=130 Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Breast Cancer · Colorectal Cancer · Lung Cancer
Primary: Retention — 53.8; 67.7 percentage of participants
Phase 2 N=234 RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Acute Schizophrenia · Schizoaffective Disorder
Primary: Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score — 87.57; 88.74; 85.88; 91.68 scores on a scale
N/A N=56 Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion
Dental Erosion · Acid Wear
Primary: Relative Erosion Resistance (RER) of Enamel Specimens Post 4 Hours of Treatment Exposure — -36.66; -36.53; -36.98; -77.82 Percentage RER — p=<0.0001
Phase 4 N=334 Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension
Primary: Time to First Confirmed Morbidity/Mortality Event up to the End of Study — 96.1; 90.6; 90.5; 83.0 percentage of participants-Kaplan Meier — p=0.2508
Phase 2 N=37 Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
Chronic Hepatitis C · Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With 4-week Rapid Virologic Response (RVR) — 33.3; 55.6; 70.0; 22.2 percentage of participants — p=0.336